Citius Pharma Analyst Ratings
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product Data
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Citius Pharma Analyst Ratings
Citius Pharmaceuticals Price Target Maintained With a $6.00/Share by EF Hutton
Citius Pharma Analyst Ratings
Citius Pharma Analyst Ratings
Citius Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)
Citius Pharma Analyst Ratings
Buy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug Exclusivity
Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR), Arcus Biosciences (RCUS) and Masimo (MASI)
Strong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology Spinout
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target